Check out your Company Bowl for anonymous work chats.
At PTC, the health and safety of our employees and our patients is our top priority. With the threat of COVID-19 (coronavirus) causing major global disruptions in business, travel and human welfare, we believe it is our duty as a multinational company to take necessary action to protect the health and safety of our employees and our patients, and in turn the stability of our global operations.
Give a shout out to an administrative professional who makes your work life easier. At PTC, we have an amazing team of men and women who keep our business running smoothly… in rough waters and calm. Thank you. Happy #AdministrativeProfessionalsWeek! #OnePTC
According to Statista, female employees only occupy between 28 and 42% of the total workforce at the largest tech companies in the United States (statista.com/chart/4467/female-employees-at-tech-companies/). PTC’s CIO has some advice for #womenintech who are trying to get ahead. Check it out! #womeninSTEM #womenleaders
"We are in this for the long-term, and, while we must always recognize the need for resources to fund our mission, delivering treatments that can extend the lives of patients is what drives our passion to never give up and work harder every day to reach that goal."
Coronavirus may be keeping PTC employees home…but we’re still engaged! And we're still hiring!
PTC is hiring! We’ve got a great mission and great people. Plus, we’ve got many chances to eat great food. YUM! If you want to join an important cause, check out our job openings and apply today.
PTC is growing…fast! HR SVP Martin Rexroad has some ideas about how diversity and compassion form the backbone of our #OnePTC approach. Read all about it!
We take pride in our employees’ dedication to improving the lives of our patients. We’re honored that Senior Vice President of Corporate Relations Mary Frances Harmon has been recognized with the third annual Heart of BioNJ Award for putting patients first.
Real world data from the STRIDE registry in Duchenne Muscular Dystrophy have now been published in the Journal for Comparative Effectiveness Research. At PTC, making a real difference to the lives of patients and families affected by rare disease is central to what drives all of us.
We're excited to share our FIREFISH clinical trial results which demonstrate how the investigational therapy risdiplam can help type 1 spinal muscular atrophy (SMA) infant patients! SMA is a severe, progressive neuromuscular disease and the most common genetic cause of infant mortality.
